APR 29 2027
Immunome — varegacestat $IMNM
for desmoid tumors (locally aggressive soft-tissue tumors)
Accepted JUL 8 2026.
About
Desmoid tumors are rare, non-metastatic growths that arise from connective tissue cells and can become locally aggressive, invading nearby soft tissues and sometimes compressing vital organs to cause pain or life-threatening problems. Varegacestat is an oral drug designed to inhibit the gamma-secretase enzyme. By blocking this enzyme, the drug may interfere with a key cellular signaling pathway that drives tumor growth, potentially offering a way to control these invasive tumors.
Pivotal trial
The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on varegacestat
- Why Immunome (IMNM) Is Down 8.2% After FDA Accepts Varegacestat NDA With Strong Phase 3 Data - simplywall.st
- Why Immunome (IMNM) Is Up 11.7% After FDA Accepts Varegacestat NDA For Desmoid Tumors - Sahm
- FDA Accepts NDA for Varegacestat in Desmoid Tumors - OncLive
- FDA Accepts Immunome's NDA for Varegacestat in Desmoid Tumors, Setting Up an April 2027 Decision - Oncodaily
- FDA Accepts NDA for Varegacestat in Desmoid Tumors - Targeted Oncology
Sponsor Watch — recent news on Immunome
- Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
- Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
- Immunome (IMNM) Is Down 12.7% After Phase 3 Varegacestat Data And FDA NDA Filing - Has The Bull Case Changed?